scholarly journals Plasma Hemostasis in Patients with Essential Hypertension and Non-alcoholic Fatty Liver Disease Under Conditions of Hypercholesterolemia and Concomitant Statin Therapy

2021 ◽  
pp. 12-18
Author(s):  
Vasyl Netyazhenko ◽  
Nataliia Bazhenova
Keyword(s):  
Essential Hypertension ◽  
Liver Disease ◽  
Fatty Liver ◽  
Statin Therapy ◽  
Fatty Liver Disease ◽  
The Other ◽  
Alcoholic Fatty Liver ◽  
At Iii ◽  
Fibrinolytic Potential ◽  
Alcoholic Fatty Liver Disease

In the modern scientific world, it has been proven that non-alcoholic fatty liver disease (NAFLD) is a marker of the risk of cardiovascular (CV) events, and therefore, attention and control of risk factors for CV diseases is important. Considering the prevalence of atherogenic dyslipidemias and their proven effect on the development of thrombotic CV complications in patients with NAFLD, it is important to understand the role of hemostatic blood activity. The objective: To increase the efficiency of early diagnosis of thrombophilic changes in the blood in patients with essential hypertension (HT) combined with non-alcoholic fatty liver disease by determining the state of plasma hemostasis in conditions of hypercholesterolemia and concomitant statin therapy. Materials and methods. 152 patients were examined. Patient groups: I – 46 patients with stage II hypertension, II – 54 patients with NAFLD without hypertension, group III – 52 patients with stage II hypertension with concomitant NAFLD. Results. The growth of prothrombogenic activity of the blood among all groups of patients, however, with HT II stage, combined with NAFLD, the most significant effect was carried out precisely on the final stages of coagulation. An increase in the level of fibrinogen was observed in patients with grade II hypertension. by 29,3 % (p<0,01) and with a combination of HT and NAFLD by 39,7 % (p<0,001). The levels of soluble fibrin-monomeric complexes in all groups were significantly higher than the control values: in patients with hypertension. – 4,1 times (p<0,001), with NAFLD – 2,8 times (p<0,001), in the NAFLD group with hypertension – 4,5 times (p<0,001). Antithrombin III (AT III) was reduced by 12,3 % (p<0,01) relative to the control only in patients with hypertension. On the other hand, the fibrinolytic potential was reduced among all examined groups. Determination of the effect of lipid-lowering therapy revealed an acceleration of prothrombin time (PTT) by 19.2 % (p<0,01) in patients with NAFLD without statin treatment. In the general cohort, statin use increased the activity of AT III by 10,7 % (p<0,01), but in the NAFLD group, this difference was more significant – by 14,3 % (p<0,001). In patients with comorbid course of HT and NAFLD with cholesterolemia level <5 mmol/L, we observed an increase in PTT by 32,5 % (p<0,05), INR by 25,4 % (p<0,05) and thrombin time by 23,2 % (p<0,05) during statin therapy. On the other hand, in the subgroup with hypercholesterolemia, statins increased the activity of the anticoagulant link of hemostasis – the level of ATIII increased by 3,1 % (p<0,05). Conclusions. Depletion of the fibrinolytic potential against the background of activation of the coagulant hemostasis link is observed in patients with hypertension combined with NAFLD. In the case of concomitant hypercholesterolemia, the procoagulant activity of the blood increases, however, against the background of treatment with statins, there is a decrease in the coagulation potential of the blood and an increase in the activity of the anticoagulant link of hemostasis.

scholarly journals Evaluation of Thyroid Function Status in Sonographically Suggested Fatty Liver Subjects

2018 ◽  
Vol 18 (2) ◽  
pp. 125-130
Author(s):  
Farhana Rahman ◽  
Sanowar Hossain ◽  
Shankar Kumar Biswas ◽  
Fatema Sultana Haque ◽  
Rubina Begum ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Thyroid Function ◽  
Fatty Liver Disease ◽  
The Other ◽  
Alcoholic Fatty Liver ◽  
The Mean ◽  
Thyroid Hormone Levels ◽  
Grade 3 ◽  
Alcoholic Fatty Liver Disease

Objectives: The liver metabolizes thyroid hormones and thereby influences the regulation of their systematic endocrine effects. On the other hand, thyroid hormones play an important role in hepatic lipid homeostasis. Several studies addressed the association between thyroid function tests and non alcoholic fatty liver disease. The results of those studies indicate that hypothyroidism might be related to non alcoholic fatty liver disease. The recognized link between hypothyroidism and elements of metabolic syndrome may explain this relation. The present study was performed to evaluate the thyroid function status with the severity of sonographically suggested fatty liver subjects.Materials and Methods: This cross sectional study was carried out at the Institute of Nuclear Medicine and Allied Sciences (INMAS) of Dhaka Medical College Hospital Campus, Dhaka during the period of January 2014 to December 2014. A total number of 155 consecutive patients having sonographically detected fatty liver from the above mentioned hospitals were included in this study and they were divided into three grades depending on the sonographic criteria. Data were analyzed between these three grades in respect of age, sex, BMI, thyroid hormone levels (FT3, FT4 and TSH), fasting lipid profile and serum liver enzyme levels.Results: 82 (52.9%) patients had grade 1, 50 (32.3%) had grade 2 and 23 (14.8%) had grade 3 fatty liver. The mean age was found 39±10.9 years in Grade 1, 39.5±10.4 years in Grade 2 and 41.4±7.1 years in Grade 3. The difference was not statistically significant (p>0.05) among three groups. Male to female ratio was almost 2:3 in the whole study subjects. The mean BMI was significantly higher in grade 3 (p<0.05) followed by grade 2 and grade 1. 128 (82.6%) patients were euthyroid, 23 (14.8%) were subclinical hypothyroid and 4 (2.6%) were hypothyroid. In Anova test, the mean FT3 and FT4 were significantly declined (p<0.05) with increased grade but the mean TSH level was significantly increased (p=0.001) with increased grade of fatty liver. The Spearman’s rank correlation test shows that no significant but a negative correlation (r= -0.101; p=0.175) was found between FT3 and fatty liver of the study patients, but a significant negative correlation (r=-0.277; p=0.001) was observed between FT4 and fatty liver of the study patients. On the other hand a significant positive correlation (r=0.325; p=0.001) was observed between TSH and fatty liver of the study patients.Conclusion: In this study it has been found that thyroid hormone levels are significantly decreased with increasing grades of fatty liver detected by ultrasound. The underlying pathophysiology for this association is still not clear, however several mechanisms have been proposed. So the findings of this study will inspire other researchers to evaluate the thyroid function status with the severity of sonographically suggested fatty liver in larger scale.Bangladesh J. Nuclear Med. 18(2): 125-130, July 2015

scholarly journals EVALUATION OF THYROID FUNCTION STATUS IN SONOGRAPHICALLY SUGGESTED FATTY LIVER SUBJECTS

2020 ◽  
pp. 1-3
Author(s):  
Amrendra Kumar Singh ◽  
Gagan Gunjan ◽  
Rajkamal Choudhary ◽  
Debarshi Jana
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Thyroid Function ◽  
Fatty Liver Disease ◽  
The Other ◽  
Alcoholic Fatty Liver ◽  
The Mean ◽  
Thyroid Hormone Levels ◽  
Grade 3 ◽  
Alcoholic Fatty Liver Disease

Objectives: The liver metabolizes thyroid hormones and thereby influences the regulation of their systematic endocrine effects. On the other hand, thyroid hormones play an important role in hepatic lipid homeostasis. Several studies addressed the association between thyroid function tests and non alcoholic fatty liver disease. The results of those studies indicate that hypothyroidism might be related to non alcoholic fatty liver disease. The recognized link between hypothyroidism and elements of metabolic syndrome may explain this relation. The present study was performed to evaluate the thyroid function status with the severity of sonographically suggested fatty liver subjects. Materials and Methods: This cross sectional study was carried out at the Department of Medicine of Jawaharlal Nehru Medical College & Hospital, Bhagalpur, Bihar during the period of June 2019 to May 2020. A total number of 155 consecutive patients having sonographically detected fatty liver from the above mentioned hospitals were included in this study and they were divided into three grades depending on the sonographic criteria. Data were analyzed between these three grades in respect of age, sex, BMI, thyroid hormone levels (FT3, FT4 and TSH), fasting lipid profile and serum liver enzyme levels. Results: 82 (52.9%) patients had grade 1, 50 (32.3%) had grade 2 and 23 (14.8%) had grade 3 fatty liver. The mean age was found 39±10.9 years in Grade 1, 39.5±10.4 years in Grade 2 and 41.4±7.1 years in Grade 3. The difference was not statistically significant (p>0.05) among three groups. Male to female ratio was almost 2:3 in the whole study subjects. The mean BMI was significantly higher in grade 3 (p<0.05) followed by grade 2 and grade 1. 128 (82.6%) patients were euthyroid, 23 (14.8%) were subclinical hypothyroid and 4 (2.6%) were hypothyroid. In Anova test, the mean FT3 and FT4 were significantly declined (p<0.05) with increased grade but the mean TSH level was significantly increased (p=0.001) with increased grade of fatty liver. The Spearman’s rank correlation test shows that no significant but a negative correlation (r= -0.101; p=0.175) was found between FT3 and fatty liver of the study patients, but a significant negative correlation (r=-0.277; p=0.001) was observed between FT4 and fatty liver of the study patients. On the other hand a significant positive correlation (r=0.325; p=0.001) was observed between TSH and fatty liver of the study patients. Conclusion: In this study it has been found that thyroid hormone levels are significantly decreased with increasing grades of fatty liver detected by ultrasound. The underlying pathophysiology for this association is still not clear, however several mechanisms have been proposed. So the findings of this study will inspire other researchers to evaluate the thyroid function status with the severity of sonographically suggested fatty liver in larger scale.

scholarly journals Protective effects of fractional extracts from Panellus serotinus on non-alcoholic fatty liver disease in obese, diabetic db/db mice

2011 ◽  
Vol 107 (5) ◽  
pp. 639-646 ◽  
Author(s):  
Masashi Inafuku ◽  
Koji Nagao ◽  
Saori Nomura ◽  
Bungo Shirouchi ◽  
Nao Inoue ◽  
...  
Keyword(s):  
Liver Disease ◽  
Serum Level ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
De Novo ◽  
Water Soluble ◽  
The Other ◽  
Alcoholic Fatty Liver ◽  
The Metabolic Syndrome ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is emerging as the most common liver disease in industrialised countries. Various mushrooms have been used in Eastern folk medicine for the treatment of lifestyle diseases. We previously found that the dietary intake of powdered whole Panellus serotinus (Mukitake) alleviates NAFLD in obese, diabetic db/db mice. In the present study, we investigated the influence of Mukitake fractional extracts on the development of NAFLD in db/db mice. A significant reduction in the hepatic TAG content, macrovesicular hepatocytes and activities of key enzymes for de novo synthesis of the fatty acid was observed in both the water-soluble Mukitake extract (WE) diet and the ethanol-soluble Mukitake extract (EE) diet groups compared with the control diet group of the db/db mice. The serum level of monocyte chemoattractant protein-1 (MCP-1), which is known to exacerbate insulin resistance, was significantly decreased in the WE group. On the other hand, the serum level of adiponectin, which plays a protective role against the metabolic syndrome, was significantly increased in the EE group. Additionally, differential analysis between Mukitake and Shiitake, mycelia from the same family, using liquid chromatography time-of-flight MS technology revealed that only seven and five compounds exist in WE and EE from Mukitake, respectively. In conclusion, the present study demonstrated that Mukitake displays at least two different physiological actions that alleviate NAFLD: one through the reduction in inflammatory damage by its suppression in MCP-1 production and the other through an increase in level of serum adiponectin and the prevention of visceral fat accumulation.

Non-Alcoholic Fatty Liver Disease is Not Associated with Vitamin D Deficiency in Essential Hypertension

2013 ◽  
Vol 20 (1) ◽  
pp. 33-37 ◽  
Author(s):  
Cristiana Catena ◽  
Chiara Cosma ◽  
Valentina Camozzi ◽  
Mario Plebani ◽  
Mario Ermani ◽  
...  
Keyword(s):  
Vitamin D ◽  
Essential Hypertension ◽  
Liver Disease ◽  
Fatty Liver ◽  
Vitamin D Deficiency ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

scholarly journals GAMBARAN PENYAKIT PERLEMAKAN HATI NON-ALKOHOLIK PADA PASIEN HIPERTENSI YANG MEMPUNYAI SGPT MENINGKAT

e-CliniC ◽  
2015 ◽  
Vol 3 (1) ◽  
Author(s):  
Nathania P. Rengkung ◽  
Bradley J. Waleleng ◽  
Stella Palar
Keyword(s):  
Essential Hypertension ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Renal Hypertension ◽  
Age Group ◽  
Alcoholic Fatty Liver ◽  
Hypertensive Patients ◽  
The Metabolic Syndrome ◽  
Alcoholic Fatty Liver Disease

Abstract: Non alcoholic fatty liver disease (NAFLD) is a clinical pathologic condition that is signed by increasing of transaminase enzyme serum level and hepatic steatosis without any history of alcohol consuming. Essential hypertension is associated with the metabolic syndrome, insulin resistance and the development of fatty liver. This study aimed to obtain the description of NAFLD in hypertensive patients that had elevation of SGPT. This was a prospective study conducted in Renal Hypertension Clinic Prof. Dr. R. D. Kandou Hospital Manado from November 2014 until January 2015. The results showed that there were 31 hypertensive patients; 21 cases were diagnosed with NAFLD. Females were more frequent than males and the age group 51-60 years was the most frequent (38.1%). Mild fatty liver was found in 17 cases, moderate in 3 cases, and severe in 1 case. Conclusion: In this study, non alcoholic fatty liver disease in hypertensive patients affected females more than males in the age group of 51-60 years old. Mild fatty liver was the most common USG result among the patients.Keywords: non-alcoholic fatty liver disease (NAFLD), essential hypertension, USGAbstrak: Penyakit perlemakan hati non-alkoholik merupakan klinikopatologik yang ditandai oleh kenaikan kadar enzim transaminase serum dan steatosis hepatik tanpa adanya riwayat konsumsi alkohol. Hipertensi esensial diketahui terkait dengan sindrom metabolik, yang ditandai adanya resistensi insulin, dan perkembangan perlemakan hati (steatosis hati). Penelitian ini dilakukan untuk mengetahui gambaran NAFLD pada pasien hipertensi dengan SGPT meningkat. Penelitian ini menggunakan metode prospektif dan dilakukan terhadap pasien hipertensi di Poliklinik Ginjal Hipertensi RSUP Prof. Dr. R. D. Kandou Manado dari bulan November 2014 - Januari 2015. Pada penelitian ini didapatkan 31 pasien hipertensi; 21 kasus pasien yang didiagnosis NAFLD. Hasil penelitian memperlihatkan bahwa dari 21 kasus NAFLD didapatkan pasien perempuan lebih banyak daripada laki-laki, dengan usia terbanyak 51-60 tahun (38,1%). Derajat perlemakan hati ringan ditemukan pada 17 kasus; derajat sedang 3 kasus; dan derajat berat 1 kasus. Simpulan: Penyakit perlemakan hati non-alkoholik pada pasien hipertensi banyak diderita oleh perempuan dengan kelompok umur 51-60 tahun. Derajat perlemakan hati ringan sebagai gambaran USG tersering pada pasien hipertensi.Kata kunci: non-alcoholic fatty liver disease (NAFLD), hipertensi esensial, USG

Effects of Acetylsalicylic Acid on Non-Alcoholic Fatty Liver Disease – Systematic Review

2019 ◽  
Vol 1 (2) ◽  
Author(s):  
Abdulrahman Ismaiel ◽  
Nahlah Al Srouji
Keyword(s):  
Systematic Review ◽  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Fatty Liver Disease ◽  
Experimental Studies ◽  
The Other ◽  
Protective Effects ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Background: Several studies have assessed the effects of acetylsalicylic acid (ASA), a widely used drug worldwide, in non-alcoholic fatty liver disease (NAFLD) patients. In this systematic review, we aim to evaluate the effect of ASA use on the prevalence of NAFLD, as well as hepatic steatosis and fibrosis in NAFLD patients. Methods: We performed a systematic search on PubMed and Embase electronic databases with predefined keywords searching for observational and experimental studies published from inception and till 19 July 2019. The diagnosis of NAFLD was based on histology, imaging or surrogate markers. Eligible articles based on inclusion and exclusion criteria were extracted and included in the qualitative assessment using the National Heart, Lung, and Blood Institute (NHLBI) quality assessment tools. Results: A total of seven observational studies (5 cross-sectional and 2 cohort) were included involving 18,209 subjects. Three studies evaluated the prevalence of NAFLD in subjects receiving ASA, out of which two studies demonstrated a lower prevalence rate in subjects using ASA for at least ≥ 15 times per month. On the other hand, only one study demonstrated no prevalence decrease in NAFLD with the use of ASA. Moreover, hepatic steatosis and fibrosis was evaluated in four studies with histological confirmation of NAFLD. Two of these studies reported a reduced severity of hepatic steatosis with ASA use. On the other hand, a study demonstrated that a less severe hepatic steatosis but not histological improvement was associated with ASA use. Furthermore, another study reported that ASA use in type 2 diabetic patients wasn’t associated with protective effects against advanced hepatic fibrosis. Statistical pooling of included studies wasn’t performed due to heterogeneity of the study designs. Conclusions: Although most studies demonstrated potential protective effects of ASA use in hepatic steatosis and fibrosis, as well as a reduced prevalence of NAFLD, results from the current literature remain inconsistent with the quality of most studies being rated as fair or poor. Therefore, clear conclusions and recommendations can’t be drawn from the current studies in the literature evaluating this association. Further experimental studies are required to confirm the potential protective effects associated with ASA use on NAFLD. ​

Sign in / Sign up

Export Citation Format

Share Document